SOLIGENIX, INC.
Close on Oct 19, 2026
- Market cap
- $5.48M
- P/E (TTM)
- –
- Dividend yield
- –
About Soligenix
Pharmaceutical Preparations, SIC 2834
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare diseases with unmet medical needs. The company operates two primary business segments: Specialized BioTherapeutics and Public Health Solutions. Its biotherapeutics pipeline includes synthetic hypericin treatments, primarily HyBryte for cutaneous T-cell lymphoma and SGX302 for psoriasis, alongside dusquetide formulations for rare inflammatory conditions. Its public health segment concentrates on biodefense medical countermeasures, including ricin toxin and filovirus vaccine candidates that utilize a proprietary heat-stabilization platform. The company's end users encompass patients suffering from rare oncology and inflammatory disorders, as well as government agencies and public defense organizations that support and procure biodefense countermeasures.
The company conducts clinical studies across multiple medical centers throughout the United States and engages in regulatory and development activities in Europe and the United Kingdom. Soligenix maintains its principal executive offices and corporate headquarters in Princeton, New Jersey.
Summary of the business section of Soligenix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SOLIGENIX, INC.
- Founded
- 1987
- Headquarters
- Princeton, NJ
- Address
- 29 Emmons Drive, Suite B-10 08540
- Phone
- (609) 538-8200
- Employees
- 14, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- SNGX
- Exchange
- Nasdaq
- Shares outstanding
- 22M, Jul 31, 2026
- Public float
- $4.59M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-16 reverse, Jun 6, 2024; 1-for-16 reverse, Jun 5, 2024; 1-for-15 reverse, Feb 10, 2023; 1-for-15 reverse, Feb 10, 2023; 1-for-10 reverse, Nov 10, 2016; 1-for-10 reverse, Oct 7, 2016; 1-for-20 reverse, Feb 1, 2012; 1-for-15 reverse, Jun 11, 1997
- SEC CIK
- 812796
- CUSIP
- 834223604
- ISIN
- US8342236044
- LEI
- 549300MN2EF9LQHLT817
- EIN
- 41-1505029
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher J. Schaber | CHAIRMAN, CEO AND PRESIDENT, Director | 15,511 |
| Jonathan L. Guarino | CFO | 11,000 |
| Richard Straube | CMO (Consulting) | 8,000 |
| Oreola Donini | CSO | – |
| Anthony Gregg Lapointe | Director | 73,781 |
| Jerome B. Zeldis | Director | 22,917 |
| Robert J. Rubin | Director | 4,385 |
| Diane L. Parks | Director | 14,940 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Christopher J. Schaber | $1.09M | $1.21M | $420.55K | $1 | – |
| FY2024 Christopher J. Schaber | $832.63K | $697.45K | $366.65K | $2 | – |
| FY2023 Christopher J. Schaber | $700.48K | $531.40K | $330.74K | $4 | – |
| FY2022 Christopher J. Schaber | $711.18K | $641.82K | $320.64K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we employed a total of 14 persons, including 1 part-time employee and 13 full-time employees, four of whom are MDs/PhDs.”
Corporate history
Events identified from SEC filings